文献速递肾小球疾病急性肾损伤

抗过氧化物酶体抗体在肺肾综合征中的抑制作用

Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes.
PubMed 文献 · J Am Soc Nephrol · 2018-10-02

该研究探讨了肺肾综合征(如Goodpasture综合征)患者血清中抗过氧化物酶体(peroxidasin)自身抗体的存在及其功能。通过ELISA和竞争结合实验,发现患者血清在疾病临床出现前及出现时均存在抗过氧化物酶体抗体,且富集的抗体能在体外抑制过氧化物酶体介导的次溴酸生成。这些抗体不与可溶性MPO结合,但可与包被在聚苯乙烯板上的MPO交叉反应,并也见于抗MPO血管炎患者,与更活跃的临床疾病相关。

要点

  • 抗过氧化物酶体抗体存在于Goodpasture综合征患者血清中,早于临床发病。
  • 该抗体可抑制过氧化物酶体介导的次溴酸产生,可能参与疾病活动。
  • 抗过氧化物酶体抗体与抗MPO血管炎更活跃的临床疾病显著相关。

核心结论

  • 抗过氧化物酶体抗体与肺肾综合征相关,出现在疾病活动前及活动期间,可能参与部分患者的疾病活动和发病机制。

研究设计与样本

  • 研究使用ELISA和竞争结合实验检测Goodpasture综合征患者及健康对照血清中自身抗体的存在和特异性。
  • 在患者或对照部分纯化的IgG存在下,荧光法测量过氧化物酶体活性。
  • 临床疾病严重程度采用伯明翰血管炎活动评分评估。

主要发现

  • 在Goodpasture综合征患者临床出现前和出现时的血清中检测到抗过氧化物酶体自身抗体。
  • 富集的抗过氧化物酶体抗体在体外抑制过氧化物酶体介导的次溴酸生成。
  • 抗过氧化物酶体抗体识别过氧化物酶体但不识别可溶性MPO,但与ELISA板包被的MPO交叉反应。
  • 抗过氧化物酶体特异性抗体也见于抗MPO血管炎患者血清,并与显著更活跃的临床疾病相关。

临床怎么用

  • 对于肺肾综合征患者,检测抗过氧化物酶体抗体可能有助于评估疾病活动及发病机制。
  • 抗过氧化物酶体抗体与抗MPO血管炎疾病活动相关,提示其可作为潜在生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Goodpasture syndrome (GP) is a pulmonary-renal syndrome characterized by autoantibodies directed against the NC1 domains of collagen IV in the glomerular and alveolar basement membranes. Exposure of the cryptic epitope is thought to occur via disruption of sulfilimine crosslinks in the NC1 domain that are formed by peroxidasin-dependent production of hypobromous acid. Peroxidasin, a heme peroxidase, has significant structural overlap with myeloperoxidase (MPO), and MPO-ANCA is present both before and at GP diagnosis in some patients. We determined whether autoantibodies directed against peroxidasin are also detected in GP. METHODS: We used ELISA and competitive binding assays to assess the presence and specificity of autoantibodies in serum from patients with GP and healthy controls. Peroxidasin activity was fluorometrically measured in the presence of partially purified IgG from patients or controls. Clinical disease severity was gauged by Birmingham Vasculitis Activity Score. RESULTS: We detected anti-peroxidasin autoantibodies in the serum of patients with GP before and at clinical presentation. Enriched anti-peroxidasin antibodies inhibited peroxidasin-mediated hypobromous acid production in vitro. The anti-peroxidasin antibodies recognized peroxidasin but not soluble MPO. However, these antibodies did crossreact with MPO coated on the polystyrene plates used for ELISAs. Finally, peroxidasin-specific antibodies were also found in serum from patients with anti-MPO vasculitis and were associated with significantly more active clinical disease. CONCLUSIONS: Anti-peroxidasin antibodies, which would previously have been mischaracterized, are associated with pulmonary-renal syndromes, both before and during active disease, and may be involved in disease activity and pathogenesis in some patients.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. McCall AS, Bhave G, Pedchenko V, et al. Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes. J Am Soc Nephrol. 2018. PMID: 30279272. doi:10.1681/ASN.2018050519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。